NASDAQ:AVTE Aerovate Therapeutics Q3 2024 Earnings Report $9.82 -0.70 (-6.65%) As of 07/11/2025 ProfileEarnings History Aerovate Therapeutics EPS ResultsActual EPS-$19.60Consensus EPS -$20.65Beat/MissBeat by +$1.05One Year Ago EPSN/AAerovate Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAerovate Therapeutics Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time4:00PM ETUpcoming EarningsAerovate Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Aerovate Therapeutics Earnings HeadlinesJade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 MillionApril 28, 2025 | globenewswire.comAerovate Stockholders Approve Merger Proposal With Jade BiosciencesApril 23, 2025 | nasdaq.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.July 15 at 2:00 AM | Brownstone Research (Ad)Aerovate Therapeutics stockholders approve proposed merger with Jade BiosciencesApril 23, 2025 | markets.businessinsider.comAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related ProposalsApril 21, 2025 | prnewswire.comAerovate Therapeutics declares special cash dividend, estimated $2.40 per shareApril 10, 2025 | markets.businessinsider.comSee More Aerovate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aerovate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aerovate Therapeutics and other key companies, straight to your email. Email Address About Aerovate TherapeuticsAerovate Therapeutics (NASDAQ:AVTE) is a clinical‐stage biopharmaceutical company dedicated to developing inhaled therapies for serious respiratory diseases. The company leverages a proprietary aerosol delivery platform designed to optimize drug deposition in the lungs, enabling targeted treatment for conditions such as non–cystic fibrosis bronchiectasis, severe asthma and chronic obstructive pulmonary disease. Aerovate’s development pipeline includes multiple product candidates in various stages of clinical and preclinical research, all focused on improving therapeutic outcomes while minimizing systemic side effects commonly associated with oral or intravenous administration. Founded in 2018 as a spin‐out from leading academic research programs in pulmonary medicine, Aerovate is headquartered in Boston, Massachusetts, with additional research facilities in the San Francisco Bay Area. The company has established strategic collaborations with academic institutions and contract research organizations across North America and Europe to advance its inhaled drug delivery technology. Aerovate’s R&D efforts center on harnessing novel small molecules and biologics, reformulated for inhalation, to treat both infectious and inflammatory lung conditions. Aerovate’s leadership team is comprised of industry veterans with deep expertise in respiratory drug development and inhalation device engineering. Chief Executive Officer Dr. Jane Carter brings over 25 years of experience in biotech leadership, having previously held senior roles at global pharmaceutical companies. The company’s board includes experts in pulmonology, drug delivery science and regulatory affairs, guiding Aerovate through late‐stage clinical trials and toward commercialization.Written by Jeffrey Neal JohnsonView Aerovate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings ASML (7/16/2025)Kinder Morgan (7/16/2025)U.S. Bancorp (7/16/2025)Bank of America (7/16/2025)Prologis (7/16/2025)Morgan Stanley (7/16/2025)Johnson & Johnson (7/16/2025)The PNC Financial Services Group (7/16/2025)Progressive (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
